ACHL Key Statistics, Chart & Performance
The current stock price of ACHL is 1.48 USD. In the past month the price increased by 6.47%. In the past year, price increased by 15.63%.
ACHL Latest News, Press Relases and Analysis
ACHL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About ACHL
Company Profile
Achilles Therapeutics Plc is a biopharmaceutical company engaged in developing transformative precision T-cell therapies to treat multiple types of solid tumors. The firm has been developing artificial intelligence (AI)-powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The firm has used DNA sequencing data from each patient, together with its proprietary PELEUS bioinformatics platform, to identify clonal neoantigens specific to that patient, to enable and support development of product candidates specifically targeting those clonal neoantigens.
Company Info
ACHILLES THERAPEUTICS PL-ADR
245 Hammersmith Road, Gunnels Wood Road
London W6 8PW GB
CEO: Iraj Ali
Employees: 210
Phone: 442081544600
ACHILLES THERAPEUTICS PL-ADR / ACHL FAQ
What does ACHL do?
Achilles Therapeutics Plc is a biopharmaceutical company engaged in developing transformative precision T-cell therapies to treat multiple types of solid tumors. The firm has been developing artificial intelligence (AI)-powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The firm has used DNA sequencing data from each patient, together with its proprietary PELEUS bioinformatics platform, to identify clonal neoantigens specific to that patient, to enable and support development of product candidates specifically targeting those clonal neoantigens.
What is the current price of ACHL stock?
The current stock price of ACHL is 1.48 USD. The price increased by 0.68% in the last trading session.
Does ACHL stock pay dividends?
ACHL does not pay a dividend.
What is the ChartMill rating of ACHILLES THERAPEUTICS PL-ADR stock?
ACHL has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is ACHL stock listed?
ACHL stock is listed on the Nasdaq exchange.
How is the market expecting ACHL stock to perform?
6 analysts have analysed ACHL and the average price target is 6.12 USD. This implies a price increase of 313.51% is expected in the next year compared to the current price of 1.48.
What is the Price/Earnings (PE) ratio of ACHILLES THERAPEUTICS PL-ADR (ACHL)?
ACHILLES THERAPEUTICS PL-ADR (ACHL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.65).
ACHL Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ACHL. When comparing the yearly performance of all stocks, ACHL is one of the better performing stocks in the market, outperforming 94.71% of all stocks.
ACHL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACHL. ACHL has a great financial health rating, but its profitability evaluates not so good.
ACHL Financial Highlights
Over the last trailing twelve months ACHL reported a non-GAAP Earnings per Share(EPS) of -1.65. The EPS increased by 12.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.52% | ||
| ROE | -64.84% | ||
| Debt/Equity | 0 |
ACHL Forecast & Estimates
6 analysts have analysed ACHL and the average price target is 6.12 USD. This implies a price increase of 313.51% is expected in the next year compared to the current price of 1.48.